Shots:
- The US FDA approved Itovebi + Ibrance & fulvestrant as a 1L treatment in adults with endocrine-resistant, PIK3CA-mutated, HR+ & HER2- locally advanced or metastatic breast cancer, based on the P-III (INAVO120) trial
- P-III (INAVO120) trial assessed the safety and efficacy of Itovebi + Ibrance & fulvestrant vs PBO + Ibrance & fulvestrant (n= 325) and showed a 57% reduction in disease worsening or death vs palbociclib & fulvestrant alone as 1L treatment; the trial met its 1EP (PFS) & 2EPs (ORR & CBR) with OS follow-up continuing for the next analysis
- Results from INAVO120 are also being used for submissions to other global health authorities. Additionally, the company is evaluating Itovebi in two more P-III trials (INAVO121 & INAVO122) for the same indication
Ref: Roche | Image: Roche | Press Release
Related News:- GE HealthCare Reports the US FDA’s Approval of Flyrcado (Flurpiridaz F 18) PET Radiotracer for Improved CAD Diagnosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
